PETACH TIKVA, Israel, April 20, 2016 /PRNewswire/ --

Macrocure Ltd. (NASDAQ: MCUR) ("Macrocure" or the "Company"), a clinical-stage biotechnology company, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2015 with the U.S. Securities and Exchange Commission (the "SEC"). The annual report on Form 20-F, which contains Macrocure's audited financial statements, can be accessed on the SEC's website at http://www.sec.gov, as well as via the Company's investor relations website at http://investor.macrocure.com/annuals-proxies.cfm. The Company will deliver a hard copy of its annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Shai Lankry, the Company's Chief Financial Officer, at +972-3-923-5556, or Shai@Macrocure.com.

About Macrocure Ltd. 

Macrocure Ltd. is a clinical-stage biotechnology company that until recently was focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds. For more information, please visit http://www.Macrocure.com. 


            For Investors: 
        Shai Lankry 
        Macrocure Ltd. 
        Shai@macrocure.com  
        +972-3-7631409 

 

SOURCE Macrocure Ltd.